Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and …
RS McIntyre, JD Rosenblat… - American Journal of …, 2021 - Am Psychiatric Assoc
Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …
with major depressive disorder. Despite the proven efficacy of monoamine-based …
Long-term safety of ketamine and esketamine in treatment of depression
Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …
Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system
C Gastaldon, E Raschi, JM Kane, C Barbui… - Psychotherapy and …, 2020 - karger.com
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Depression: Biological markers and treatment
Nowadays depression is considered as a systemic illness with different biological
mechanisms involved in its etiology, including inflammatory response, hypothalamic …
mechanisms involved in its etiology, including inflammatory response, hypothalamic …
Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders
The emerging roles of ketamine and esketamine as effective rapid-acting antidepressants
hold promise for patients suffering from treatment-resistant depression and/or major …
hold promise for patients suffering from treatment-resistant depression and/or major …
Mental health-related risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology …
KH Ladwig, TC Baghai, F Doyle… - European Journal of …, 2022 - academic.oup.com
The prevalence and public health burden of chronic heart failure (CHF) in Europe is steadily
increasing mainly caused by the ageing population and prolonged survival of patients with …
increasing mainly caused by the ageing population and prolonged survival of patients with …
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge …
S Kasper, WJ Cubała, A Fagiolini… - The World Journal of …, 2021 - Taylor & Francis
Objectives Despite the available therapies for treatment-resistant depression (TRD), there
are a limited number that are evidence-based and effective in this hard-to-treat population …
are a limited number that are evidence-based and effective in this hard-to-treat population …
The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: a randomized controlled trial
H Yang, Q Zhao, H Chen, W Liu, T Ding… - British Journal of …, 2022 - Wiley Online Library
Aims Propofol may result in hypotension, bradycardia and loss of protective reflexes,
especially in elderly patients, while esketamine, a N‐methyl‐D‐aspartate receptor …
especially in elderly patients, while esketamine, a N‐methyl‐D‐aspartate receptor …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC psychiatry, 2021 - Springer
Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …
antidepressants (ADs) is approved in the European Union, United States, and other markets …
[HTML][HTML] Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis
SM Wang, NY Kim, HR Na, HK Lim… - Clinical …, 2021 - ncbi.nlm.nih.gov
Objective We performed a meta-analysis of randomized double-blinded placebo controlled
trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major …
trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major …